Post 9/11 Autoimmune Disease Risk

Save

The 9/11/01 terrorist attach on the World Trade Center (WTC)  resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage.  Arthritis & Rheumatology reports that dust cloud exposure among responders and

Guselkumab a Hit in Phase III for PsA

Save

The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.

Low Risk with Immunosuppression at Surgery

Save

The Annals of Rheumatic Disease reports that rheumatoid arthritis patients on biologic therapies do not have a greater risk of postoperative infection after hip fracture, abdominopelvic or cardiac surgery compared (compared with those on methotrexate alone) and that glucocorticoids were associated with a dose-dependent increase risk for postoperative infections.

RheumNow Podcast – The Beginning of Something Else (4.10.20)

Save

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Coagulopathy and Antiphospholipid Antibodies with Covid-19

Save

The New England Journal of Medicine has featured a report of three COVID infected patients, who developed peripheral and central infarcts with a antiphospholipid antibodies. 

TNR - Grand Rounds: Safety of Biologics & New Agents

Save

On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures.  The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".

Incubation Period for COVID-19

Save

The incubation period for coronavirus disease 2019 (COVID-19) has important implications for surveillance and control activities. The Annals of Internal Medicine reports a pooled analysis of confirmed COVID-19 cases January 4, 2020 and February 24, 2020.

Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

Save

A phase III study of the nerve growth factor and monoclonal antibody tanezumab showed positive results in a refractory patient population with knee or hip osteoarthritis (OA) -- good enough that this agent may finally be approved after a long and rocky development road.

COVID-19 Susceptibility: Why Do Some Become So Ill?

Save

The differential susceptibility to COVID-19 infection is attributable to socioeconomic factors and genetic differences, that together with environmental factors, human-virus interactions, gender, perhaps blood type, and age-related senescence determine the immune response and the likelihood of developing disease.

NICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic

Save

On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.

The Immunologic Basis of Wellness in the COVID-19 Era

Save

We indeed are living in interesting times and we all are seeking not to contract COVID-19 - this is logical. While our goal is to avoid infection, I think we all must agree that our aspirations must encompass more than disease avoidance. What we should be seeking now, as well, is more than absence of disease but rather a state of optimal wellness.

COVID Town Hall Meeting for Rheumatology

Save

On Thursday, April 2nd, RheumNow hosted its' first Town Hall Meeting for Rheumatologist, with this 90 minute discussion devoted to the COVID-19 crisis as it affects Rheumatologists.